Balyasny Asset Management
NTLA icon

Balyasny Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Balyasny Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-492,100
Closed -$5.74M – 3140
2024
Q4 		$5.74M Buy
+492,100
New +$7.68M 0.01% 1203
2022
Q4 		– Sell
-10,000
Closed -$560K – 3080
2022
Q3 		$560K Buy
+10,000
New +$620K ﹤0.01% 2002

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management's NTLA Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 169,286 shares worth $2.17M. The stake represents ﹤0.01% of the portfolio and ranks #1742 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in NTLA as recently as Q3 2025.

Balyasny Asset Management first reported a position in NTLA in Q4 2018 and has held it in 15 quarters since. The position peaked at $26.9M in Q4 2024. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Balyasny Asset Management held 169,286 shares of Intellia Therapeutics worth $2.17M as of Q1 2026.
  • Intellia Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1742 holding.
  • Balyasny Asset Management first reported a position in Intellia Therapeutics in Q4 2018 and has held it in 15 quarters since.
  • Balyasny Asset Management's Intellia Therapeutics position peaked at $26.9M in Q4 2024.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.